Arne Skag

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    Charles H Chesnut III
    Osteoporosis Research Group, University of Washington, Seattle, Washington 98185, USA
    J Bone Miner Res 19:1241-9. 2004
  2. ncbi Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age
    Mark P Ettinger
    Radiant Research and Regional Osteoporosis Center of South Florida, 2081 SE Ocean Boulevard, Stuart, FL, USA
    J Rheumatol 32:1968-74. 2005

Detail Information

Publications2

  1. ncbi Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    Charles H Chesnut III
    Osteoporosis Research Group, University of Washington, Seattle, Washington 98185, USA
    J Bone Miner Res 19:1241-9. 2004
    ..Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate...
  2. ncbi Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age
    Mark P Ettinger
    Radiant Research and Regional Osteoporosis Center of South Florida, 2081 SE Ocean Boulevard, Stuart, FL, USA
    J Rheumatol 32:1968-74. 2005
    ..We investigated the effect of age on the safety profile of oral daily and intermittent ibandronate, with particular emphasis on the upper gastrointestinal (GI) safety profile of ibandronate...